Since 2006, AABB has been a leader in the establishment of the US national hemovigilance program, from its beginning as a public-private collaboration for the program design to the implementation of a system to track adverse reactions and incidents associated with blood collection and transfusion. AABB has a role in recipient hemovigilance through the AABB Center for Patient Safety, a component Patient Safety Organization (PSO) of the AABB, the only nationally listed PSO dedicated to transfusion safety. Through collecting and analyzing adverse events in the context of transfusion, trends and best practices can be identified and interventions developed to significantly improve patient care and safety.
AABB coordinates the AABB Donor Hemovigilance Program to collect and analyze adverse reactions associated with blood donation. Additional vigilance programs include the West Nile Virus, Chagas Disease, and Zika Virus Biovigilance Networks and the AABB Blood Survey, a statistically validated survey of blood collection and utilization by the AABB membership.